SBOT / Serve Robotics Inc. - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results TORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2025 and provided an update on its business. During

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 EDESA BIOTECH, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Form of Subordinated Note (included in Exhibit 4.4).**

Exhibit 4.4 EDESA BIOTECH, INC., as Issuer and [●], as Trustee INDENTURE Dated as of [●] Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between EDESA BIOTECH, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and

Calculation of Filing Fee Tables.**

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) EDESA BIOTECH, INC.

As filed with the Securities and Exchange Commission on July 25, 2025

As filed with the Securities and Exchange Commission on July 25, 2025 Registration No.

Form of Senior Note (included in Exhibit 4.3).**

Exhibit 4.3 EDESA BIOTECH, INC., as Issuer and [●], as Trustee INDENTURE Dated as of [●] Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and (d) 310(c) Inapplicable 31

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Edesa Biotech, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

Amendment No. 4 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

Exhibit 10.1 AMENDMENT NO. 4 TO EDESA BIOTECH, INC. 2019 EQUITY INCENTIVE COMPENSATION PLAN This Amendment No. 4 to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 18, 2025 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corporation (the “Company”). RECITALS WHEREAS, the Company previously adopted

As filed with the Securities and Exchange Commission on May 28, 2025

As filed with the Securities and Exchange Commission on May 28, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 EDESA BIOTECH, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

Consulting Agreement, dated May 12, 2025, between Edesa Biotech Research, Inc. and Stephen Lemieux (filed herewith).

Exhibit 10.4 Consulting Agreement This Consulting Agreement (the “Agreement”) is entered into as of May 12, 2025 (the “Effective Date”), by and between Edesa Biotech Research, Inc., an Ontario corporation, having its principal place of business at 100 Spy Court, Markham, Ontario L3R 5H6 Canada (the “Company”), and Stephen Lemieux, principally located at [**] (the “Consultant”). The Company and the

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results TORONTO, May 14, 2025 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2025 and provided an update on its business. During t

Edesa Biotech Announces Chief Financial Officer Transition

EXHIBIT 99.1 Edesa Biotech Announces Chief Financial Officer Transition TORONTO, April 04, 2025 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succee

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2025 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commiss

Employment Agreement, dated April 3, 2025, by and between the Company and Peter Weiler (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 4, 2025, and incorporated herein by reference).

Exhibit 10.1 Employment Agreement THIS AGREEMENT is made as of April 3, 2025, with effect from May 1, 2025. Between: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (hereinafter referred to as "the Employer" or “the Company”) AND Peter Weiler of [**] (hereinafter referred to as "the Employee") WHEREAS the Employer wishes to offer employment to th

Edesa Biotech, Inc. 7,812,496 Common Shares

PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-285539 Edesa Biotech, Inc. 7,812,496 Common Shares This prospectus relates to the resale from time to time, by the selling shareholders identified herein (the “Selling Shareholders”) of up to (i) 3,468,746 of our common shares, no par value (the “Shares”) and (ii) 4,343,750 of our common shares (the “Conversion Shares”) issuable upon

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 March 7, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Edesa Biotech, Inc. Registration Statement on Form S-3 (File No. 333-285539) Filed on March 4, 2025 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933

As filed with the Securities and Exchange Commission on March 4, 2025

As filed with the Securities and Exchange Commission on March 4, 2025 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Edesa Biotech, Inc.

Notice of Articles

Exhibit 3.7 Mailing Address: PO Box 9431 Stn Prov Govt Victoria BC V8W 9V3 www.corporateonline.gov.bc.ca Location: 2nd Floor - 940 Blanshard Street Victoria BC 1 877 526-1526 CERTIFIED COPY Of a Document filed with the Province of British Columbia Registrar of Companies Notice of Articles BUSINESS CORPORATIONS ACT T.K. SPARKS This Notice of Articles was issued by the Registrar on: February 13, 202

Exhibit A

Edesa Biotech, Inc. 100 Spy Court, Markham, Ontario L3R 5H6 (289) 800-9600 | www.edesabiotech.com February 26, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Tracie Mariner Vanessa Robertson Re: Edesa Biotech, Inc. Form 10-K for Fiscal Year Ended September 30, 2024 File No. 001-3761

AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G

EXHIBIT 99 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer.

JOINT FILING AGREEMENT

EX-99.3 2 ex993to13d12927027021825.htm JOINT FILING AGREEMENT Exhibit 99.3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Shares, without par value, of

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2025 Results TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2024 and provided an update on its business. During the q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, IN

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 Edesa Biotech,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2025 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Amended Articles of Edesa Biotech, Inc. (included as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on February 13, 2025, and incorporated herein by reference).

Exhibit 3.1 EDESA BIOTECH, INC. (the “Company”) THE FOLLOWING IS AN EXTRACT OF RESOLUTIONS OF THE DIRECTORS OF THE COMPANY CONSENTED TO IN WRITING ON FEBRUARY 11, 2025 AND EFFECTIVE AS OF FEBRUARY 12, 2025 “NOW, THEREFORE, BE IT RESOLVED THAT: Amendment to Articles to Create Series B - 1 Convertible Preferred Shares 4. 319406.00024/311950351.1 The authorized share structure of the Company be amend

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Exhibit 99.1 Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules Financing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insiders Capital raise to fund Edesa’s CXCL10 antibody program through the end of fiscal 2026 TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq: EDSA) (

Form of Investor Rights Agreement, dated February 12, 2025, between Edesa Biotech, Inc. and the investors signatory thereto (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).

Exhibit 10.2 INVESTOR RIGHTS AGREEMENT THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of February 12, 2025, by and among Edesa Biotech, Inc., a company organized under the laws of British Columbia (the “Company”), and the purchasers set forth on Schedule 1 hereto (each, a “Purchaser”, and collectively, the “Purchasers”), and shall become effective as of the Closing D

Form of Securities Purchase Agreement, dated February 12, 2025, between Edesa Biotech, Inc. and the investors signatory thereto (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 12, 2025, between Edesa Biotech, Inc., a British Columbia corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

-09-30FY2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Insider Trading Policy.

Exhibit 19.1 EDESA BIOTECH, INC. INSIDER TRADING POLICY As Amended and Restated by the Board on December 12, 2024 The following Insider Trading Policy (“Policy”) has been approved by the Board of Directors (the “Board”) of EDESA BIOTECH, INC. (together with its subsidiaries, the “Company”). 1. PURPOSE OF THE POLICY. This Policy provides guidelines with respect to transactions in the Company’s secu

Edesa Biotech Reports Fiscal Year 2024 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2024 Results TORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2024 and provided an update on its business. During the fiscal y

Notice of Articles of Edesa Biotech, Inc.

Exhibit 3.7

Exhibit 4.11

Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital shares summarizes the material terms and provisions of our capital shares based on the provisions of our Amended and Restated Articles (as amended, the “Articles”). The following description of our capital shares does not purport

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 EDESA BIOTECH,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (Exa

EDSA / Edesa Biotech, Inc. / Nijhawan Pardeep - SC 13D/A Activist Investment

SC 13D/A 1 sc13da110124.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L306 (CUSIP Number) Dr. Pardeep Nijhawan c/o Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, L3R 5H6, Canada (289) 8

Form of Common Share Purchase Warrant issued to Pardeep Nijhawan Medicine Professional Corporation or its assigns on October 30, 2024 (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on October 30, 2024, and incorporated herein by reference).

Exhibit 4.1 UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE . NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMEN

Amended and Restated Articles of Edesa Biotech, Inc.

Exhibit 3.1 319406.00024/309750857.1 EDESA BIOTECH, INC. (the “Company”) THE FOLLOWING IS AN EXTRACT OF RESOLUTIONS OF THE DIRECTORS OF THE COMPANY CONSENTED TO IN WRITING ON OCTOBER 30, 2024 AND EFFECTIVE AS OF OCTOBER 30, 2024 “NOW, THEREFORE, BE IT RESOLVED THAT: Amendment to Articles to Reflect Amended Terms of Series A - 1 Convertible Preferred Shares 5. The Alteration is approved whereby: (a

Securities Purchase Agreement, dated October 30, 2024, by and between Edesa Biotech, Inc. and Pardeep Nijhawan Medicine Professional Corporation (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 31, 2024, and incorporated herein by reference).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 30, 2024, between Edesa Biotech, Inc., a British Columbia corporation (the “Company”), and Pardeep Nijhawan Medicine Professional Corporation (the “Purchaser”). WHEREAS the Company desires to issue to the Purchaser, and the Purchaser desires to acquire from the Company, units (th

Edesa Biotech’s Founder Makes Strategic Investment in the Company

EXHIBIT 99.1 Edesa Biotech’s Founder Makes Strategic Investment in the Company TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that the company has entered into a purchase agreement with an entity affiliated with Par Nijhawan, MD

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 3, 2024 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commi

At The Market Offering Agreement, dated October 4, 2024, by and between Edesa Biotech, Inc. and H.C. Wainwright & Co., LLC (included as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on October 4, 2024, and incorporated herein by reference).

Exhibit 1.1 AT THE MARKET OFFERING AGREEMENT October 4, 2024 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Edesa Biotech, Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms

Up to $3,870,000 Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-266604 PROSPECTUS SUPPLEMENT (To Prospectus dated August 12, 2022) Up to $3,870,000 Common Shares We have entered into an At The Market Offering Agreement dated October 4, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright” or the “Sales Agent”), relating to our common shares, no par value (“common shares”), offered by th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) - Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2024 and provided an update on its business. During

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2024 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 24, 2024 EDESA BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commiss

BARDA Selects Edesa Biotech’s Drug for U.S. Funded Platform Trial in General ARDS

EXHIBIT 99.1 BARDA Selects Edesa Biotech’s Drug for U.S. Funded Platform Trial in General ARDS · This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. · This BARDA-funded project is expected to complement Edesa’s ongoing drug development activities in COVID-19 ARDS. · Paridiprubart was sel

EDSA / Edesa Biotech, Inc. / SATTERFIELD THOMAS A JR - SC 13G Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Edesa Biotech, Inc. (Name of Issuer) Common Stock, no par value per share (Title of Class of Securities) 27966L306 (CUSIP Number) May 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

As filed with the Securities and Exchange Commission on May 31, 2024

As filed with the Securities and Exchange Commission on May 31, 2024 Registration No.

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Edesa Biotech, Inc.

Amendment No. 3 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 30, 2024, and incorporated herein by reference).

EXHIBIT 10.1 AMENDMENT NO. 3 TO EDESA BIOTECH, INC. 2019 EQUITY INCENTIVE COMPENSATION PLAN This Amendment No. 3 to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 20, 2024 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corporation (the “Company”). RECITALS WHEREAS, the Company previously adopted

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2024

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2024 EDESA BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2024 EDESA BIOTECH, INC. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC.

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During

ARS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

ARS - PDF COPY

2023 Annual Report Dear Fellow Shareholders, 2023 was a year full of progress and milestones in the development of our host-directed therapeutic platforms.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2024 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, IN

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2024 Results TORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three months ended December 31, 2023 and provided an update on its business. During t

CA27966L3065 / Edesa Biotech, Inc. / Velan Capital Investment Management LP Passive Investment

SC 13G/A 1 d1093840513g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Edesa Biotech, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 27966L306 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de

CA27966L3065 / Edesa Biotech, Inc. / Pardeep Nijhawan Medicine Professional Corp - FORM SC 13D/A Activist Investment

SC 13D/A 1 edsasc13da.htm FORM SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L306 (CUSIP Number) Dr. Pardeep Nijhawan c/o Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, L3R 5H6, Canada (289

Edesa Biotech Reports Fiscal Year 2023 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2023 Results TORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the fiscal year ended September 30, 2023 and provided an update on its business. During the yea

Incentive Compensation Repayment (Clawback) Policy (included as Exhibit 97.1 to the Company’s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).

EXHIBIT 97.1 EDESA BIOTECH, INC. COMPENSATION RECOVERY POLICY (Adopted and approved on November 27, 2023) 1. Purpose Edesa Biotech, Inc. (collectively with its subsidiaries, the “Company”) is committed to promoting high standards of honest and ethical business conduct and compliance with applicable laws, rules and regulations. As part of this commitment, the Company has adopted this Compensation R

Strategic Innovation Fund Agreement, dated October 12, 2023, by and among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and his Majesty the King in right of Canada as represented by the Minister of Industry (included as Exhibit 10.33 to the Company’s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).

EXHIBIT 10.33 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [**] INDICATES THAT INFORMATION HAS BEEN REDACTED. STRATEGIC INNOVATION FUND EB05 Therapeutic This Agreement made Between: HIS MAJESTY THE KING IN RIGHT OF CANADA (“His Majesty”) as represented

Description of Securities (filed herewith).

EXHIBIT 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital shares summarizes the material terms and provisions of our capital shares based on the provisions of our Amended and Restated Articles (the “Articles”). The following description of our capital shares does not purport to be comple

First Amendment to Amended and Restated Employment Agreement, by and between the Company and Pardeep Nijhawan, dated December 7, 2023 (included as Exhibit 10.36 to the Company’s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).

EXHIBIT 10.36 FIRST AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 7th day of December, 2023. BETWEEN: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (the “Employer”) OF THE FIRST PART - and - PARDEEP NIJHAWAN, of the City of Markham, in the Province of Ontario (the “Employee”) OF THE SECOND PART WHEREAS: A. Th

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (Exa

First Amendment to Exclusive License Agreement, dated as of September 21, 2023, by and between Edesa Biotech Research, Inc. and Dr. Saul Yedgar (included as Exhibit 10.35 to the Company’s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).

EXHIBIT 10.35 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS A TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [**] INDICATES THAT INFORMATION HAS BEEN REDACTED. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This First Amendment (“First Amendment”), effective as of September 21, 2023 (“Effective Date”),

Form of Common Share Purchase Warrant issued to H.C. Wainwright & Co., Inc. designees on June 7, 2019 (included as Exhibit 4.12 to the Company’s Annual Report on Form 10-K filed on December 15, 2023, and incorporated herein by reference).

EXHIBIT 4.12 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 25, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 20, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Credit Agreement, effective as of October 20, 2023, by and between the Company and Pardeep Nijhawan Medicine Professional Corporation (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on October 23, 2023, and incorporated herein by reference).

EXHIBIT 10.1 CREDIT AGREEMENT THIS CREDIT AGREEMENT made as of the 20th day of October, 2023. BETWEEN: PARDEEP NIJHAWAN MEDICINE PROFESSIONAL CORPORATION, a corporation incorporated under the laws of the Province of Ontario (hereinafter referred to collectively as the “Lender”) - and - EDESA BIOTECH, INC., a corporation incorporated under the laws of the Province of Ontario (hereinafter referred t

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Exhibit 99.2 Edesa Biotech Secures $10 Million Credit Facility with Company Founder · Revolving Line of Credit to Support Completion of Government-Funded ARDS Study TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA) (“Edesa”, or the “Company”), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced it has entered

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Exhibit 99.1 Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government TORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23 million from the Government of Canada for a pivotal Phase 3 clinical study of the company’s

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Edesa Biotech Announces One-for-Seven Reverse Share Split

EXHIBIT 99.1 Edesa Biotech Announces One-for-Seven Reverse Share Split TORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA) (“Edesa” or the “Company”), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today is announcing that it intends to effect a one-for-seven reverse share split of its common shares. The Company’s common

Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

EDSA / Edesa Biotech Inc / Pardeep Nijhawan Medicine Professional Corp - SC 13D/A Activist Investment

SC 13D/A 1 edsasc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L108 (CUSIP Number) Dr. Pardeep Nijhawan c/o Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, L3R 5H6, Canada (289) 800

Amended and Restated Employment Agreement, by and between the Company and Michael Brooks, dated August 4, 2023 (included as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed on August 9, 2023, and incorporated herein by reference).

EXHIBIT 10.4 Amended and Restated Employment Agreement THIS AMENDED AND RESTATED AGREEMENT is made as of August 4, 2023 (the “Agreement”), and amends and replaces in its entirely the employment agreement between the Company (as defined below) and the Employee (as defined below) made as of June 14, 2019, as amended on March 19, 2021 and April 12, 2022 (the “Old Employment Agreement”); Between: EDES

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal Third Quarter 2023 Results TORONTO, ON / ACCESSWIRE / August 9, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2023 and provided an update on its business. During the fiscal third quarter,

Amended and Restated Employment Agreement, by and between the Company and Pardeep Nijhawan, dated August 4, 2023 (included as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 9, 2023, and incorporated herein by reference).

EXHIBIT 10.3 Amended and Restated Employment Agreement THIS AMENDED AND RESTATED AGREEMENT is made as of August 4, 2023 (the “Agreement”) and amends and replaces in its entirely the employment agreement between the Company (as defined below) and the Employee (as defined below) made as of June 14, 2019, as amended on March 19, 2021 and April 12, 2022 (the “Old Employment Agreement”); Between: EDESA

Employment Agreement by and between the Company and Stephen Lemieux, dated June 26, 2023 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on June 27, 2023, and incorporated herein by reference).

EXHIBIT 10.1 Employment Agreement THIS AGREEMENT is made as of June 26, 2023, with effect from July 15, 2023. Between: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (hereinafter referred to as "the Employer" or “the Company”) AND Stephen Lemieux of the Town of Oakville, in the Province of Ontario (hereinafter referred to as "the Employee") WHER

Edesa Biotech Appoints Biotech Deal Veteran to CFO Role

EXHIBIT 99.1 Edesa Biotech Appoints Biotech Deal Veteran to CFO Role TORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of directors has appointed Stephen Lemieux, CPA to the role of Chief Financial Officer, effective July 15, 2023. He

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 26, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 22, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

Amendment No. 2 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan

EXHIBIT 10.1 AMENDMENT NO. 2 TO EDESA BIOTECH, INC. 2019 EQUITY INCENTIVE COMPENSATION PLAN This Amendment No. 2 to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this “Amendment”) is made and entered into effective as of March 1, 2023 (the “Effective Date”), by Edesa Biotech, Inc., a British Columbia corporation (the “Company”). RECITALS WHEREAS, the Company previously adopted t

Filing Fee Table

U.S. Securities and Exchange Commission You’ve Exceeded the SEC’s Traffic Limit Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains

As filed with the Securities and Exchange Commission on May 24, 2023

S-8 1 edsas8.htm FORM S-8 As filed with the Securities and Exchange Commission on May 24, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada N/A (State or other jurisdiction of incorporat

Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results TORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2023 and provided an update on its business. During the fiscal second quarter, the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC.

ARS

ARS

Addressing Unmet Medical Needs in In ammatory and Immmue-Related Diseases 2022 Annual Report Dear Fellow Shareholders, 2022 was a year of ongoing progress, and anticipation.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

Equity Distribution Agreement, dated as of March 27, 2023, by and between Edesa Biotech, Inc. and Canaccord Genuity LLC (included as Exhibit 1.1 to the Company’s Current Report on Form 8-K filed on March 27, 2023, and incorporated herein by reference).

Exhibit 1.1 Edesa Biotech, Inc. Common Shares, without par value, Having an Aggregate Offering Price of up to US$20,000,000 EQUITY DISTRIBUTION AGREEMENT March 27, 2023 Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Edesa Biotech, Inc., a company incorporated pursuant to the laws of the Province of British Columbia, Canada (the “Company”), confir

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 Edesa Biotech, Inc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Up to $8,370,000 Common Shares

Filed Pursuant to Rule 424(b)(5) Registration No. 333-266604 PROSPECTUS SUPPLEMENT (To Prospectus dated August 12, 2022) Up to $8,370,000 Common Shares We have entered into an Equity Distribution Agreement, or the Distribution Agreement, with Canaccord Genuity LLC, or Canaccord, acting as sales agent, on March 27, 2023, relating to our common shares, no par value (the “Common Shares”) offered by t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001

Description of Securities (filed herewith).

Exhibit 4.11 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of our capital shares summarizes the material terms and provisions of our capital shares based on the provisions of our Amended and Restated Articles (the “Articles”). The following description of our capital shares does not purport to be comple

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2023

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2023 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, IN

Lease Extending and Amending Agreement dated as of December 31, 2022 by and between Edesa Biotech Research, Inc. and 1968160 Ontario, Inc. (included as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on February 10, 2023 and incorporated herein by reference).

EXHIBIT 10.3 LEASE EXTENDING AND AMENDING AGREEMENT THIS AGREEMENT made as of the 31st day December, 2022 (the “Effective Date”). BETWEEN: 1968160 ONTARIO INC. (the “Landlord”) OF THE FIRST PART - and - EDESA BIOTECH RESEARCH, INC. (the “Tenant”) OF THE SECOND PART WHEREAS by a lease dated the 1st day of January, 2017 (the “Lease”), the Landlord did demise and lease unto the Tenant for a term of s

Edesa Biotech Reports Fiscal 1st Quarter 2023 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2023 Results TORONTO, ON / ACCESSWIRE / February 10, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2022 and provided an update on its business. During the fiscal first quarter, the

EDSA / Edesa Biotech Inc / Lumira Capital Investment Management Inc. - SC 13D/A Activist Investment

SC 13D/A 1 brhc10046676sc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L108 (CUSIP Number) Vasco Larcina c/o Lumira Capital Investment Management 141 Adelaide Street West, Suite 770 Tor

EDSA / Edesa Biotech Inc / Velan Capital Investment Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Edesa Biotech, Inc. 5,382,667 Common Shares

424B3 1 tm2233254d1424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-268847 PROSPECTUS Edesa Biotech, Inc. 5,382,667 Common Shares This prospectus relates to the resale from time to time, by the selling shareholders identified in this prospectus under the caption “Selling Shareholders,” of up to (i) 2,691,337 of our common shares, no par value (the “Shares”), (i) 1,345,665 comm

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 December 21, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Edesa Biotech, Inc. Registration Statement on Form S-3 (File No. 333-268847) Filed on December 16, 2022 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2022

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal Year 2022 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2022 Results TORONTO, ON / ACCESSWIRE / December 16, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2022 and provided an update on its business. During the fiscal year, Edesa reported posit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (Exa

Third Amendment to Exclusive License Agreement, dated October 26, 2022, by and between the Registrant and Yissum Research Development Company (included as Exhibit 10.11 to the Company’s Annual Report on Form 10-K filed on December 16, 2022 and incorporated herein by reference).

EXHIBIT 10.11 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This Third Amendment (“Third Amendment”), effective as of October 26, 2022 (“Effective Date”), is entered into by and between Yissum Research and Development Co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter)

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 2834 N/A (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Empl

Joint Filing Agreement, dated as of November 8, 2022 by and among (i) Pardeep Nijhawan Medicine Professional Corporation, formed in Ontario, Canada, (ii) The Digestive Health Clinic Inc., formed in Ontario, Canada, (iii) 1968160 Ontario Inc., formed in Ontario, Canada, (iv) The New Nijhawan Family Trust 2015 and (v) Dr. Pardeep Nijhawan, an individual.

EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.

EDSA / Edesa Biotech Inc / Pardeep Nijhawan Medicine Professional Corp - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L108 (CUSIP Number) Dr. Pardeep Nijhawan c/o Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, L3R 5H6, Canada (289) 800-9600 (Name, Address and Telephone

Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

Exhibit 99.1 Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market TORONTO, ON / ACCESSWIRE / November 3, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private placement directly with investors priced at-the-market und

Form of U.S. Subscription Agreement (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).

Exhibit 10.2     Form of Subscription Agreement for US Accredited Investors        NON-BROKERED PRIVATE PLACEMENT OF UNITS   SUBSCRIPTION AGREEMENT   INSTRUCTIONS   1. Complete and sign the Execution Page (which follows this cover page) of the Subscription Agreement.   2. Complete and sign Schedule “A” if you are a US individual accredited investor required to do so.   3. Provide payment of the pu

Form of Class B Warrant (included as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).

Exhibit 4.2   “UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MARCH 3, 2023.”   “NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Form of Non-U.S. Subscription Agreement (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).

Exhibit 10.1   Form of Subscription Agreement for Accredited Investors (Canadian and Non-US Residents)       NON-BROKERED PRIVATE PLACEMENT OF UNITS   SUBSCRIPTION AGREEMENT   INSTRUCTIONS   1. Complete and sign the Execution Page (which follows this cover page) of the Subscription Agreement.   2. Complete and sign Exhibit 1 (Certificate of Accredited Investors) and initial next to the appropriate

Form of Class A Warrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on November 3, 2022 and incorporated herein by reference).

Exhibit 4.1   “UNLESS PERMITTED UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE THE SECURITY BEFORE MARCH 3, 2023.”   “NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES ONG><>ONT size=2>SECURITIES AND EXCHANGE COMMISSION ONT>ONG> Washington, D.

Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results ? Phase 3 ARDS drug study in hospitalized Covid-19 patients expanded ? Company reaffirms guidance on completion of Phase 2b dermatology drug study TORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today repo

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 August 10, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Edesa Biotech, Inc. Registration Statement on Form S-3 (File No. 333-266604) Filed on August 5, 2022 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1

As filed with the Securities and Exchange Commission on August 5, 2022

As filed with the Securities and Exchange Commission on August 5, 2022 Registration No.

Form of Subordinated Note (included in Exhibit 4.4).**

Exhibit 4.4 EDESA BIOTECH, INC., as Issuer and [?], as Trustee INDENTURE Dated as of [?] Subordinated Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between EDESA BIOTECH, INC. and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and

Form of Senior Note (included in Exhibit 4.3).**

Exhibit 4.3 EDESA BIOTECH, INC., as Issuer and [?], as Trustee INDENTURE Dated as of [?] Senior Debt Securities CROSS REFERENCE SHEET1 Between Provisions of the Trust Indenture Act of 1939 and the Indenture to be dated as of , 20 between and , as Trustee: Section of the Act Section of Indenture 310(a)(1) and (2) 5.08 310(a)(3) and (4) Inapplicable 310(b) 5.09(a), (b) and (d) 310(c) Inapplicable 31

Calculation of Filing Fee Tables.**

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) EDESA BIOTECH, INC.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES ONG>SECURITIES AND EXCHANGE COMMISSIONONG> Washington, D.C. 20549 FORM 10-Q

UNITED STATES ONG>SECURITIES AND EXCHANGE COMMISSIONONG> Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTEC

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).

EXHIBIT 10.2 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 12th day of April, 2022. BETWEEN: EDESA BIOTECH USA, INC., a company incorporated pursuant to the laws of the State of California (the ?Employer?) OF THE FIRST PART - and - KATHI NIFFENEGGER, of the City of Morro Bay, in the State of California (the ?Employee?) OF THE SECOND PART WHEREAS: A. The parties hereto have en

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Michael Brooks and Edesa Biotech USA, Inc. (included as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).

EXHIBIT 10.3 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 12th day of April, 2022. BETWEEN: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (the ?Employer?) OF THE FIRST PART - and - MICHAEL BROOKS, of the City of Toronto, in the Province of Ontario (the ?Employee?) OF THE SECOND PART WHEREAS: A. The parties hereto have ent

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its business. For its critical care drug candidate,

Amendment to Employment Agreement, entered into on April 12, 2022, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q filed on May 13, 2022, and incorporated herein by reference).

EXHIBIT 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 12th day of April, 2022. BETWEEN: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (the ?Employer?) OF THE FIRST PART - and - PARDEEP NIJHAWAN, of the City of Markham, in the Province of Ontario (the ?Employee?) OF THE SECOND PART WHEREAS: A. The parties hereto have e

2,739,727 common shares Issuable upon Exercise of Outstanding Warrants

Filed Pursuant to Rule 424(b)(4) Registration No. 333-264235 PROSPECTUS 2,739,727 common shares Issuable upon Exercise of Outstanding Warrants This prospectus relates to the resale from time to time, by the selling shareholder identified in this prospectus under the caption ?Selling Shareholder,? of up to 2,739,727 of our common shares, no par value, it may acquire upon the exercise of outstanding

April 15

April 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 4720 100 F Street, N.

As filed with the Securities and Exchange Commission on April 11, 2022

S-1 1 tm2212122d1s1.htm FORM S-1 As filed with the Securities and Exchange Commission on April 11, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 2834 N/A (State or other jurisdiction

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Edesa Biotech, Inc.

Notice of Articles of Edesa Biotech, Inc.

Exhibit 3.7 Mailing Address: Location: PO Box 9431 Stn Prov Govt 2nd Floor - 940 Blanshard Street Victoria BC V8W 9V3 Victoria BC www.corporateonline.gov.bc.ca 1 877 526-1526 Notice of Articles BUSINESS CORPORATIONS ACT This Notice of Articles was issued by the Registrar on: April 1, 2022 10:11 AM Pacific Time Incorporation Number: C0867178 Recognition Date and Time: Continued into British Columbi

our Definitive Proxy Statement on Schedule 14A filed with the SEC on April 1, 2022;

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Form of Placement Agent Warrant (included as Exhibit 4.3 to the Company’s Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).

Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Form of Securities Purchase Agreement, dated March 21, 2022, by and between the Company and the Purchaser (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of March 21, 2022, between Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHERE

Form of Pre-Funded Warrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on March 23, 2022 and incorporated herein by reference).

Exhibit 4.1 PRE-FUNDED COMMON SHARE PURCHASE WARRANT EDESA Biotech, inc. Warrant Shares: Initial Exercise Date: March , 2022 THIS PRE-FUNDED COMMON SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date s

Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Exhibit 99.1 Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutio

Form of Private Placement Warrant (included as Exhibit 4.2 to the Company’s Current Report on Form 8-K filed on March 23, 2022, and incorporated herein by reference).

Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

1,540,000 Common Shares Pre-Funded Warrants to Purchase up to 1,199,727 Common Shares

424B5 1 tm2210153d2424b5.htm 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2019) Filed Pursuant to Rule 424(b)(5) Registration No. 333-233567 1,540,000 Common Shares Pre-Funded Warrants to Purchase up to 1,199,727 Common Shares We are offering 1,540,000 common shares, no par value, (the “Common Shares”) in this offering. Each Common Share is being sold at a price of $3.65. We are

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

First Amendment to Equity Distribution Agreement, dated as of March 4, 2022, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC.

Exhibit 1.1 FIRST AMENDMENT TO EQUITY DISTRIBUTION AGREEMENT March 4, 2022 RBC Capital Markets, LLC 200 Vesey Street, 8th Floor New York, New York 10281 Attention: Equity Capital Markets Ladies and Gentlemen: This First Amendment (this ?Amendment?) to the Equity Distribution Agreement, dated as of November 22, 2021 (the ?Equity Distribution Agreement?), by and between Edesa Biotech, Inc., a compan

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commiss

Up to $15,400,000 Common Shares

PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2019) Filed Pursuant to Rule 424(b)(5) Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Edesa Biotech Reports Fiscal 1st Quarter 2022 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2022 Results TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended December 31, 2021 and provided an update on its business. During the quarter, Health Canada app

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, IN

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February14, 2022 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH, INC. (Exa

Edesa Biotech Reports Fiscal Year 2021 Results

EXHIBIT 99.1 Edesa Biotech Reports Fiscal Year 2021 Results TORONTO, ON / ACCESSWIRE / December 28, 2021/ Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the fiscal year ended September 30, 2021 and provided an update on its business. During the fiscal year, Edesa reported favora

Up to $10,700,000 Common Shares

PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2019) Filed Pursuant to Rule 424(b)(5) Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 28, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Equity Distribution Agreement, dated as of November 22, 2021, by and between Edesa Biotech, Inc. and RBC Capital Markets, LLC.

EX-1.1 2 tm2133613d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 Edesa Biotech, Inc. Common Shares, without par value, Having an Aggregate Offering Price of up to $15,000,000 USD EQUITY DISTRIBUTION AGREEMENT November 22, 2021 RBC Capital Markets, LLC 200 Vesey Street, 8th Floor New York, New York 10281 Attention: Equity Capital Markets Ladies and Gentlemen: Edesa Biotech, Inc., a company incorporated pursua

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Up to $15,000,000 Common Shares

424B5 1 tm2133613d2424b5.htm 424B5 PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2019) Filed Pursuant to Rule 424(b)(5) Registration No. 333-233567 Up to $15,000,000 Common Shares We have entered into an Equity Distribution Agreement, or the sales agreement, with RBC Capital Markets, LLC, or RBCCM, relating to our common shares, no par value (the “Common Shares”) offered by this prospec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOTECH, INC. (E

Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results

Exhibit 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2021 Financial Results TORONTO, ON / ACCESSWIRE / August 13, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and nine months ended June 30, 2021 and provided an update on its business. During the quarter, the

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commi

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 edsa8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdic

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Par Nijhawan and Edesa Biotech, Inc. (included as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).

Exhibit 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 19th day of March, 2021. BETWEEN: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (the ?Employer?) OF THE FIRST PART - and - PAR NIJHAWAN, of the City of Markham, in the Province of Ontario (the ?Employee?) OF THE SECOND PART WHEREAS: A. The parties hereto have entered into

Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results

Exhibit 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2021 Results TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an update on its business. The company reported that it has enro

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Kathi Niffenegger and Edesa Biotech USA, Inc. (included as Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).

Exhibit 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT This agreement (the ?Amendment?) is entered into by and between Kathi Niffenegger (?Employee?) and Edesa Biotech USA, Inc. (the ?Company?) to amend the employment agreement entered into by Employee and the Company as of December 1, 2020 (the ?Agreement?), and shall be effective as of the date executed by the parties. For good and valuable consideratio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOT

Amendment to Employment Agreement, entered into on March 19, 2021, by and between Michael Brooks and Edesa Biotech, Inc. (included as Exhibit 10.5 to the Company’s Quarterly Report on Form 10-Q filed on May 14, 2021, and incorporated herein by reference).

Exhibit 10.5 AMENDMENT TO EMPLOYMENT AGREEMENT THIS AGREEMENT is made the 19th day of March, 2021. BETWEEN: EDESA BIOTECH INC., a company incorporated pursuant to the laws of the Province of British Columbia (the ?Employer?) OF THE FIRST PART - and - MICHAEL BROOKS, of the City of Toronto, in the Province of Ontario (the ?Employee?) OF THE SECOND PART WHEREAS: A. The parties hereto have entered in

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 22, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

- FORM S-8

As filed with the Securities and Exchange Commission on April 23, 2021 Registration No.

Amendment No. 1 to Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 23, 2021, and incorporated herein by reference).

Exhibit 10.1 AMENDMENT NO. 1 TO EDESA BIOTECH, INC. 2019 EQUITY INCENTIVE COMPENSATION PLAN This Amendment to the Edesa Biotech, Inc. 2019 Equity Incentive Compensation Plan (this ?Amendment?) is made and entered into effective as of March 1, 2021 (the ?Effective Date?), by Edesa Biotech, Inc., a British Columbia corporation (the ?Company?). RECITALS WHEREAS, the Company previously adopted the Ede

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Exclusive License Agreement, dated as of March 16, 2021, by and between the Edesa Biotech Research, Inc. and Dr. Saul Yedgar (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on March 22, 2021, and incorporated herein by reference).

Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. EXCLUSIVE LICENSE AGREEMENT by and between Dr. Saul Yedgar and EDESA BIOTECH RESEARCH INC. March 16, 2021 TABLE OF CONTENTS Page Article 1 DEFINITIONS 1 Article 2 SCOPE 7 2.1 Scope. 7 Article 3 PRODUCT DEVELO

our definitive proxy statement on Schedule 14A dated March 3, 2021, filed with the SEC on March 3, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

To stop receiving updates from this company click here to unsubscribe. ACCESSWIRE | 500 Perimeter Park Drive, Suite D, Morrisville, NC 27560 | [email protected] | 1.888.952.4446

Exhibit 99.2 Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million TORONTO, ON / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announ

Underwriting Agreement

Exhibit 1.1 Edesa Biotech, Inc. 1,562,500 Common Shares (no par value per share) Amended and Restated Underwriting Agreement February 25, 2021 H.C. Wainwright & Co., LLC As Representative of the several Underwriters listed in Schedule A hereto 430 Park Avenue, 4th Floor New York, NY 10022 Ladies and Gentlemen: Edesa Biotech, Inc., a company incorporated under the laws of British Columbia, Canada (

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

To stop receiving updates from this company click here to unsubscribe. ACCESSWIRE | 500 Perimeter Park Drive, Suite D, Morrisville, NC 27560 | [email protected] | 1.888.952.4446

Exhibit 99.2 Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million TORONTO, ON / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that, due to demand, the underwriter has agreed to increase the size of the previously announ

The date of this prospectus supplement is February 25, 2021.

Filed Pursuant to Rule 424(b)(5) Registration No. 333-233567 Supplement No. 1 Dated February 25, 2021 To Prospectus Supplement dated September 28, 2020 (To Prospectus dated September 12, 2019) This Supplement No. 1 to Prospectus Supplement supplements and amends the Prospectus Supplement dated September 28, 2020 (the “ATM Prospectus Supplement”) filed by us. This Supplement No. 1 to Prospectus Sup

To stop receiving updates from this company click here to unsubscribe. ACCESSWIRE | 500 Perimeter Park Drive, Suite D, Morrisville, NC 27560 | [email protected] | 1.888.952.4446

Exhibit 99.1 Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares TORONTO, ON / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agr

1,562,500 Common Shares

PROSPECTUS SUPPLEMENT (To Prospectus dated September 12, 2019) Filed Pursuant to Rule 424(b)(5) Registration No.

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

8-K/A 1 tm218114d18k.htm FORM 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619

Edesa Biotech Increases Previously Announced Bought Deal Offering of Common Shares to $10.0 Million

Free Writing Prospectus dated February 25, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 25, 2021 Registration Statement No.

To stop receiving updates from this company click here to unsubscribe. ACCESSWIRE | 500 Perimeter Park Drive, Suite D, Morrisville, NC 27560 | [email protected] | 1.888.952.4446

Exhibit 99.1 Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares TORONTO, ON / ACCESSWIRE / February 25, 2021 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agr

Form of Underwriter Warrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K/A filed on February 26, 2021 and incorporated herein by reference).

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

Edesa Biotech Announces $3.5 Million Bought Deal Offering of Common Shares

Free Writing Prospectus dated February 25, 2021 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus Supplement dated February 25, 2021 Registration Statement No.

SUBJECT TO COMPLETION, DATED FEBRUARY 25, 2021

The information in this preliminary prospectus supplement is not complete and may be changed.

Edesa Biotech Reports Fiscal First Quarter 2021 Results

EX-99.1 2 edsaex991.htm PRESS RELEASE ISSUED BY EDESA BIOTECH, INC. DATED FEBRUARY 16, 2021. Exhibit 99.1 Edesa Biotech Reports Fiscal First Quarter 2021 Results TORONTO, ON / ACCESSWIRE / February 16, 2021 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three months ended

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOTECH, INC

Edesa Biotech Receives C$14 million for COVID-19 Study

EX-99.1 3 edsaex991.htm PRESS RELEASE Exhibit 99.1 Edesa Biotech Receives C$14 million for COVID-19 Study TORONTO, ON / ACCESSWIRE / February 2, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has secured a commitment of up to C$14 million (US$ 11 million) from the Government of Canada to complete the Phase 2 portion of a Phase 2/Phase 3 clinical study of its

Strategic Innovation Fund Agreement among Edesa Biotech Research, Inc., Edesa Biotech, Inc., and her Majesty the Queen in right of Canada as represented by the Minister of Industry, dated February 2, 2021 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 3, 2021, and incorporated herein by reference).

EX-10.1 2 edsaex101.htm STRATEGIC INNOVATION FUND AGREEMENT SIF AGREEMENT NO. 811-513437 Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. STRATEGIC INNOVATION FUND EB05 Therapeutic This Agreement made Between: HER MAJESTY THE QUEEN IN RIGHT OF CANADA (“Her

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 2, 2021 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Subsidiaries of Edesa Biotech, Inc. (included as Exhibit 21 to the Company’s Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).

Exhibit 21 EDESA BIOTECH, INC. AND SUBSIDIARIES Entity State of Incorporation/ Organization Edesa Biotech Research, Inc. Ontario, Canada Edesa Biotech USA, Inc. California, USA

Annual Report - ANNUAL REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37619 EDESA BIOTECH

Edesa Biotech Reports Fiscal Year 2020 Results

Exhibit 99.1 Edesa Biotech Reports Fiscal Year 2020 Results TORONTO, ON / ACCESSWIRE / December 7, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the fiscal year ended September 30, 2020 and provided an update on its business. During the fiscal year, Edesa added two Phase 2-ready biologics to its development pipeline, wit

Financial Statements and Exhibits, Results of Operations and Financial Condition - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Comm

Employment Agreement by and between the Company and Kathi Niffenegger, dated December 1, 2020 (included as Exhibit 10.21 to the Company’s Annual Report on Form 10-K filed on December 7, 2020, and incorporated herein by reference).

Exhibit 10.21 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of December 1, 2020 (“Effective Date”), by and between Kathi Niffenegger ( “Employee”) and Edesa Biotech USA, Inc. (formerly Stellar Biotechnologies, Inc.), a California corporation ( “Company” or “Employer”). For good and valuable consideration, the sufficiency of which is hereby acknowledged, Employ

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 1.1 Edesa Biotech, Inc. Common Shares, without par value, Having an Aggregate Offering Price of up to $9,200,000 USD EQUITY DISTRIBUTION AGREEMENT September 28, 2020 RBC Capital Markets, LLC 200 Vesey Street, 8th Floor New York, New York 10281 Attention: Equity Capital Markets Ladies and Gentlemen: Edesa Biotech, Inc., a company incorporated pursuant to the laws of the Province of British

Other Events - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Co

EDESA BIOTECH, INC. Up to $9,200,000 Common Shares

424B5 1 edsa424b5.htm PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) Registration No. 333-233567 PROSPECTUS SUPPLEMENT (to Prospectus dated September 12, 2019) EDESA BIOTECH, INC. Up to $9,200,000 Common Shares We have entered into an Equity Distribution Agreement, or the sales agreement, with RBC Capital Markets, LLC, or RBCCM, relating to our Common Shares offered by this prospectus supp

Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Co

You’ve Exceeded the SEC’s Traffic Limit

Exhibit 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements.

EDSA / Edesa Biotech, Inc. / Edesa Biotech, Inc. - SCHEDULE 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* EDESA BIOTECH, INC. (Name of Issuer) Common Shares, no par value per share (Title of Class of Securities) 27966L108 (CUSIP Number) Dr. Pardeep Nijhawan c/o Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, L3R 5H6, Canada (289) 800-9600 (Name, Address and Telephone

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOTECH, INC. (E

Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results

Exhibit 99.1 Edesa Biotech Reports Fiscal 3rd Quarter 2020 Results TORONTO, ON / ACCESSWIRE / August 12, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and nine months ended June 30, 2020 and provided an update on its business. During the quarter, Edesa received Canadian regulatory approval to begin a Phase 2/Ph

Results of Operations and Financial Condition, Financial Statements and Exhibits - CURRENT REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commi

Notice of Articles of Edesa Biotech, Inc. (included as Exhibit 3.7 to the Company’s Registration Statement on Form S-1 filed on April 11, 2022, and incorporated herein by reference)

EX-3.2 2 edsaex32.htm ARTICLES OF INCORPORATION / BYLAWS Exhibit 3.2

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 edsa8k.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdic

Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results

EX-99.1 2 edsaex991.htm PRESS RELEASE Exhibit 99.1 Edesa Biotech Reports Fiscal 2nd Quarter 2020 Results TORONTO, ON / ACCESSWIRE / May 15, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three and six months ended March 31, 2020 and provided an update on its business. Edesa reported that two new biologic drug candidat

Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOTECH, INC.

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commissi

License Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).

EX-10.1 3 edsaex101.htm LICENSE AGREEMENT Exhibit 10.1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. License Agreement dated April 17, 2020 between NovImmune SA Chemin des Aulx 14, 1228 Plan-les-Ouates, Switzerland (hereinafter NI) and Edesa Biotech Research, Inc. 10

Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders

Exhibit 99.1 Edesa Biotech and Light Chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Securities Purchase Agreement by and between Edesa Biotech, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).

EX-10.3 5 edsaex103.htm SECURITIES PURCHASE AGREEMENT Exhibit 10.3 Execution Copy CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of April 17, 2020, between Edesa Biotech, I

Purchase Agreement by and between Edesa Biotech Research, Inc. and NovImmune SA dated April 17, 2020 (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).

Exhibit 10.2 Execution Copy CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Purchase Agreement dated April 17, 2020 between NovImmune SA Chemin des Aulx 14, 1228 Plan-les-Ouates, Switzerland (hereinafter NI) and Edesa Biotech Research, Inc. 100 Spy Court, Markham, Onta

Amended and Restated Articles of Edesa Biotech, Inc. (included as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on April 23, 2020, and incorporated herein by reference).

EX-3.1 2 edsaex31.htm ARTICLES OF INCORPORATION / BYLAWS Exhibit 3.1

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Commis

Amendment No. 1 to Schedule 14A, filed with the SEC on March 24, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi

Schedule 14A dated March 23, 2020, filed with the SEC on March 23, 2020

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

EDSA / Edesa Biotech, Inc. CORRESP - -

Edesa Biotech, Inc. 100 Spy Court Markham, Ontario, Canada L3R 5H6 March 4, 2020 United States Securities and Exchange Commission Attention: Ada D. Sarmento Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 RE: Edesa Biotech, Inc. (the “Company”) Registration Statement on Form S-1 (the “Registration Statement”) File Number 333-236608 Dear Ms. Sarmento: The Company hereby re

EDSA / Edesa Biotech, Inc. S-1 - Registration Statement - REGISTRATION STATEMENT ON FORM S-1

S-1 1 edsas1.htm REGISTRATION STATEMENT ON FORM S-1 As filed with the Securities and Exchange Commission on February 25, 2020 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EDESA BIOTECH, INC. (Exact name of registrant as specified in its charter) British Columbia, Canada 2836 N/A (State

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2020 Edesa Biotech, Inc. (Exact Name of Registrant as Specified in its Charter) British Columbia, Canada 001-37619 N/A (State or Other Jurisdiction of Incorporation) (Com

EDSA / Edesa Biotech, Inc. 10-Q - Quarterly Report - QUARTERLY REPORT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37619 EDESA BIOTECH, IN

Edesa Biotech Reports Fiscal 1st Quarter 2020 Results

Exhibit 99.1 Edesa Biotech Reports Fiscal 1st Quarter 2020 Results TORONTO, ON / ACCESSWIRE / February 13, 2020 / Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company, today reported financial results for the three months ended December 31, 2019 and provided an update on its business. During the quarter, Edesa expanded an ongoing Phase 2b study of its lead product candida